Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C G Moertel

Showing results (71-80 of 251) with videos related to

Pageof 26
Sort By:
Cancer|June 15, 1990
A phase II trial of tamoxifen in hepatocellular carcinomaP F Engstrom, B Levin, C G Moertel, et al.
Cancer Treatment Reports|January 1, 1982
Pilot study of PALA and 5-FU in patients with advanced cancerM J O'Connell, G Powis, J Rubin, et al.
Cancer Treatment Reports|August 1, 1978
Phase II trial of maytansine in patients with advanced colorectal carcinomaM J O'Connell, A Shani, J Rubin, et al.
Cancer|April 1, 1979
Nonspecific immune determinants in the patient with unresectable gastrointestinal carcinomaC G Moertel, R E Ritts, M J O'Connell, et al.
Mayo Clinic Proceedings|April 1, 1980
Correlation of histopathologic characteristics of primary tumor and uninvolved regional lymph nodes in Dukes' class C colonic carcinoma with prognosisG S Thynne, L H Weiland, C G Moertel, et al.
Cancer|October 1, 1974
Usefulness of serial serum carcinoembryonic antigen (CEA) determinations during anticancer therapy or long-term follow-up of gastrointestinal carcinomaM Ravry, C G Moertel, A J Schutt, et al.
Mayo Clinic Proceedings|February 1, 1976
Who responds to sugar pills?C G Moertel, W F Taylor, A Roth, et al.
Cancer Treatment Reports|April 1, 1984
Evaluation of combined cyclophosphamide and methotrexate therapy in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndromeC G Moertel, M J O'Connell, R J Reitemeier, et al.
JAMA|July 1, 1974
Relief of pain by oral medications. A controlled evaluation of analgesic combinationsC G Moertel, D L Ahmann, W F Taylor, et al.
Cancer|August 1, 1977
Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamideC G Moertel, H O Douglas, J Hanley, et al.
Pageof 26

Showing results (71-80 of 251) with videos related to

Sort By:
Pageof 26
Cancer|June 15, 1990
A phase II trial of tamoxifen in hepatocellular carcinomaP F Engstrom, B Levin, C G Moertel, et al.
Cancer Treatment Reports|January 1, 1982
Pilot study of PALA and 5-FU in patients with advanced cancerM J O'Connell, G Powis, J Rubin, et al.
Cancer Treatment Reports|August 1, 1978
Phase II trial of maytansine in patients with advanced colorectal carcinomaM J O'Connell, A Shani, J Rubin, et al.
Cancer|April 1, 1979
Nonspecific immune determinants in the patient with unresectable gastrointestinal carcinomaC G Moertel, R E Ritts, M J O'Connell, et al.
Mayo Clinic Proceedings|April 1, 1980
Correlation of histopathologic characteristics of primary tumor and uninvolved regional lymph nodes in Dukes' class C colonic carcinoma with prognosisG S Thynne, L H Weiland, C G Moertel, et al.
Cancer|October 1, 1974
Usefulness of serial serum carcinoembryonic antigen (CEA) determinations during anticancer therapy or long-term follow-up of gastrointestinal carcinomaM Ravry, C G Moertel, A J Schutt, et al.
Mayo Clinic Proceedings|February 1, 1976
Who responds to sugar pills?C G Moertel, W F Taylor, A Roth, et al.
Cancer Treatment Reports|April 1, 1984
Evaluation of combined cyclophosphamide and methotrexate therapy in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndromeC G Moertel, M J O'Connell, R J Reitemeier, et al.
JAMA|July 1, 1974
Relief of pain by oral medications. A controlled evaluation of analgesic combinationsC G Moertel, D L Ahmann, W F Taylor, et al.
Cancer|August 1, 1977
Treatment of advanced adenocarcinoma of the pancreas with combinations of streptozotocin plus 5-fluorouracil and streptozotocin plus cyclophosphamideC G Moertel, H O Douglas, J Hanley, et al.
Pageof 26